Trial Profile
A phase II trial evaluating progression free survival with cisplatin and oral vinorelbine plus radiation for Stage III Non Small Cell Lung Cancer.
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Jun 2016
Price :
$35
*
At a glance
- Drugs Vinorelbine (Primary) ; Cisplatin
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms CoVERT
- 08 May 2009 Sponser (Pierre Fabre Medicament) identified as reported by Australian New Zealand Clinical Trials Registry record.
- 09 Jan 2009 New trial record.